I know Kite has been anxious and is well prepared for this launch with a waiting list of patients. This early approval should give them a little extra time to get the payers onboard for next year. I saw an analyst’s estimate of $200M-$250M in 2018 for Yescarta revenues, which means they are estimating about 600-700 patients at $373k per. This should mean sizable revenues for Cryoport, but unfortunately we will have to wait a few weeks for the Q3 conference call for any details.
News 
Market Data 
Discover 
